chinfloxacin

Networked: 2 relevant articles (1 outcomes, 0 trials/studies)

1.	Infections 04/01/2012 - "The high efficacy of chinfloxacin in murine systemic and local infections warrants investigation of its clinical use." 04/01/2012 - "In the mouse pulmonary infection model, chinfloxacin showed potent activity towards S. " 04/01/2012 - "In the mouse systemic infection model, chinfloxacin demonstrated potent activity against MSSA [50% effective dose (ED(50)) 2.28-4.15 mg/kg], MRSA (ED(50) 14.75 mg/kg), PISP (ED(50) 6.20 mg/kg), PRSP (ED(50) 3.51-5.03 mg/kg), VSE (ED(50) 25.02 mg/kg), VRE (ED(50) 5.18-15.39 mg/kg), E. " 04/01/2012 - "To evaluate the in vivo antibacterial efficacy of chinfloxacin, a novel fluoroquinolone, in murine systemic and local infection models. " 12/01/2018 - "Chinfloxacin hydrochloride is a novel tricyclic fluorinated quinolone in development for treatment of conventional and biothreat infections. "
2.	Peritonitis 04/01/2012 - "The efficacy of chinfloxacin in systemic infection was evaluated in a mouse peritonitis model using isolates of methicillin-susceptible Staphylococcus aureus (MSSA, n = 3), methicillin-resistant Staphylococcus aureus (MRSA; n = 1), penicillin-intermediate Streptococcus pneumoniae (PISP; n = 1), penicillin-resistant S. "